Amphastar Pharmaceuticals, Inc. (AMPH)Healthcare | Drug Manufacturers - Specialty & Generic | Rancho Cucamonga, United States | NasdaqGS
19.29 USD
+0.57
(3.045%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 19.29 |
Hot Take ↕ | July 11, 2026, 6:03 a.m. EDT
The investment case for Amphastar is currently broken by a perfect storm of regulatory headwinds and deteriorating financial performance. The company recently received an FDA warning letter regarding its IMS manufacturing facility, a critical operational blow that immediately triggered a sharp sell-off and caused analysts to slash their price targets. This regulatory overhang is compounded by a severe earnings miss where the company missed estimates by 75%, forcing a revision of future forecasts. Fundamentally, the business is struggling with flat revenue growth and a massive collapse in earnings, which has dragged the stock down nearly 45% year-over-year. While the valuation appears cheap on paper with a forward P/E under 6x, this discount reflects the market's fear of the pipeline uncertainty and the manufacturing issues rather than a margin of safety. With no dividend to provide income and a balance sheet carrying significant debt against shrinking cash flows, there is no compelling reason to deploy capital here until the regulatory clouds clear and the earnings trajectory stabilizes. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.099097 |
| AutoETS | 0.119231 |
| AutoARIMA | 0.119232 |
| MSTL | 0.130519 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.580 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 88.749 |
| Revenue per Share | 15.608 |
| Market Cap | 850,552,448 |
| Trailing P/E | 11.28 |
| Forward P/E | 6.35 |
| Beta | 0.89 |
| Profit Margins | 11.00% |
| Website | https://www.amphastar.com |
As of July 11, 2026, 6:03 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at 5.0 and 17.5) compared to negligible call activity. The implied volatility for puts is significantly elevated relative to calls, indicating a market consensus that the stock faces further pressure rather than a rally. Call volume is sparse, with no meaningful positioning for upside moves beyond the current price.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.1471526 |
| Address1 | 11,570 6th Street |
| All Time High | 67.66 |
| All Time Low | 6.67 |
| Ask | 24.55 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 3.1 - Hold |
| Average Daily Volume10 Day | 444,940 |
| Average Daily Volume3 Month | 614,986 |
| Average Volume | 614,986 |
| Average Volume10Days | 444,940 |
| Beta | 0.888 |
| Bid | 14.1 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 17.326 |
| City | Rancho Cucamonga |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.29 |
| Current Ratio | 3.853 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 19.68 |
| Day Low | 18.95 |
| Debt To Equity | 88.749 |
| Display Name | Amphastar Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,187,600 |
| Earnings Call Timestamp Start | 1,778,187,600 |
| Earnings Growth | -0.725 |
| Earnings Quarterly Growth | -0.746 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | 197,274,000 |
| Ebitda Margins | 0.27379 |
| Enterprise To Ebitda | 6.311 |
| Enterprise To Revenue | 1.728 |
| Enterprise Value | 1,244,979,456 |
| Eps Current Year | 2.62608 |
| Eps Forward | 3.03968 |
| Eps Trailing Twelve Months | 1.71 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.6624 |
| Fifty Day Average Change | -0.37239838 |
| Fifty Day Average Change Percent | -0.01893962 |
| Fifty Two Week Change Percent | -14.7152605 |
| Fifty Two Week High | 31.26 |
| Fifty Two Week High Change | -11.969999 |
| Fifty Two Week High Change Percent | -0.38291743 |
| Fifty Two Week Low | 16.65 |
| Fifty Two Week Low Change | 2.6400013 |
| Fifty Two Week Low Change Percent | 0.15855864 |
| Fifty Two Week Range | 16.65 - 31.26 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,403,703,000,000 |
| Float Shares | 32,833,792 |
| Forward Eps | 3.03968 |
| Forward P E | 6.346063 |
| Free Cashflow | 103,104,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,976 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.47344002 |
| Gross Profits | 341,128,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29742 |
| Held Percent Institutions | 0.76534 |
| Implied Shares Outstanding | 44,092,919 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. |
| Long Name | Amphastar Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 850,552,448 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_2003650 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 79,229,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 826,080,837 |
| Number Of Analyst Opinions | 6 |
| Open | 19.0 |
| Operating Cashflow | 168,878,000 |
| Operating Margins | 0.079629995 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 909 980 9484 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 19.29 |
| Post Market Time | 1,783,981,119 |
| Previous Close | 18.72 |
| Price Eps Current Year | 7.3455496 |
| Price Hint | 2 |
| Price To Book | 1.1133556 |
| Price To Sales Trailing12 Months | 1.1804539 |
| Profit Margins | 0.109960005 |
| Quick Ratio | 2.732 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.14286 |
| Region | US |
| Regular Market Change | 0.570002 |
| Regular Market Change Percent | 3.04488 |
| Regular Market Day High | 19.68 |
| Regular Market Day Low | 18.95 |
| Regular Market Day Range | 18.95 - 19.68 |
| Regular Market Open | 19.0 |
| Regular Market Previous Close | 18.72 |
| Regular Market Price | 19.29 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 375,029 |
| Return On Assets | 0.053379998 |
| Return On Equity | 0.10393 |
| Revenue Growth | 0.004 |
| Revenue Per Share | 15.608 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 44,092,919 |
| Shares Percent Shares Out | 0.0872 |
| Shares Short | 3,845,576 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,747,543 |
| Short Name | Amphastar Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1825 |
| Short Ratio | 6.04 |
| Source Interval | 15 |
| State | CA |
| Symbol | AMPH |
| Target High Price | 30.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 22.0 |
| Target Median Price | 20.5 |
| Total Cash | 291,951,008 |
| Total Cash Per Share | 6.621 |
| Total Debt | 686,377,984 |
| Total Revenue | 720,529,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.71 |
| Trailing P E | 11.280702 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.44285 |
| Two Hundred Day Average Change | -4.152849 |
| Two Hundred Day Average Change Percent | -0.17714779 |
| Type Disp | Equity |
| Volume | 375,029 |
| Website | https://www.amphastar.com |
| Zip | 91,730 |